News
Thailand has now become its second-biggest market.
It will focus on creating digital solutions for ophthalmic, neurological and psychiatric disorders.
This new funding round brings the company's total raise to roughly $62.5 million.
Only 1.3% of images included in the public data set included patient ethnicity.
Ellume began recalling the tests last month for giving false positive results.
The clinical trial results will be used to expand Viome’s mRNA platform, which in May received FDA breakthrough device designation for identifying early signs of oral and throat cancers.
The industrial giant plans to retain a stake of almost 20% in GE Healthcare.
Cue received emergency use authorization for its at-home COVID-19 test in March and went public in September.
The new funding round brings the company's valuation to $4.6 billion.
The company said the latest round brings its total raise to $47 million.